NEW YORK, Feb. 8, 2018 /PRNewswire/ --
WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on GRFS, HTBX, HEB, and IBIO which can be accessed for free by signing up to www.wallstequities.com/registration. Pre-market, WallStEquities.com covers the Biotechnology industry, which is a highly interdisciplinary field that combines biological sciences with engineering technologies to manipulate living organisms and biological systems to produce products that advances Healthcare, Medicine, Agriculture, Food, Pharmaceuticals, and Environment control. Stocks in today's lineup are: Grifols S.A. (NASDAQ: GRFS), Heat Biologics Inc. (NASDAQ: HTBX), Hemispherx Biopharma Inc. (NYSE AMER: HEB), and iBio Inc. (NYSE AMER: IBIO). All you have to do is sign up today for this free limited time offer by clicking the link below. www.wallstequities.com/registration
Grifols
Shares in Barcelona, Spain headquartered Grifols S.A. rose slightly by 0.18%, ending Wednesday's trading session at $22.83. The stock recorded a trading volume of 177,056 shares. The Company's shares have gained 31.43% over the past year. The stock is trading 4.69% above its 200-day moving average. Moreover, shares of Grifols, which develops, manufactures, and distributes a range of plasma derivative products primarily in the European Union, Spain, the US, Canada, and internationally, have a Relative Strength Index (RSI) of 35.78.
On February 06th, 2018, Grifols has received approval from the US FDA for a new higher potency formulation of its HyperRAB® rabies immune globulin [human] for rabies postexposure prophylaxis (treatment of a person immediately after exposure to the rabies virus). The new formulation is twice the potency (300 IU/mL) of currently available rabies immune globulin options. Get the full research report on GRFS for free by clicking below at: www.wallstequities.com/registration/?symbol=GRFS
Heat Biologics
Durham, North Carolina-based Heat Biologics Inc.'s stock declined 2.37%, closing the day at $2.88 with a total trading volume of 76,276 shares. The stock is trading 24.32% below their 50-day moving average. Shares of the Company, which focuses on the development and commercialization of novel allogeneic therapies for a range of cancers and infectious diseases in the US, have an RSI of 37.95.
On January 30th, 2018, Heat Biologics announced that it is hosting an analyst and investor event to present Phase-2 results from its HS-110 (viagenpumatucel-L) study in combination with the Bristol-Myers Squibb checkpoint inhibitor, nivolumab (Opdivo®), in patients with advanced non-small cell lung cancer, whose cancers have progressed after treatment with one or more lines of therapy. The presentation will take place on February 28th, 2018, at 8:00 a.m. in New York City. Access the free research report on HTBX now by signing up at: www.wallstequities.com/registration/?symbol=HTBX
Hemispherx Biopharma
On Wednesday, shares in Philadelphia, Pennsylvania headquartered Hemispherx Biopharma Inc. recorded a trading volume of 322,111 shares. The stock ended the day 1.77% higher at $0.46. The Company's shares have advanced 4.84% in the past month, 35.82% in the previous three months, and 3.43% over the past year. The stock is trading above its 50-day and 200-day moving averages by 10.17% and 6.07%, respectively. Furthermore, shares of Hemispherx Biopharma, which engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the US, have an RSI of 46.58.
On January 29th, 2018, Hemispherx Biopharma announced that Thomas K. Equels, M.S. J.D., CEO, will be presenting at the BIO CEO & Investor Conference on February 12th, 2018, at 9:15 a.m. ET (the time may be subject to changes depending on the conference organizers) at the New York Marriott Marquis in New York City. His presentation will focus on the large size of potential markets for ME/CFS; immuno-oncology; and immune system amplification for enhanced viral vaccines. Are you already registered with Wall St. Equities? Do so now for free, and get the report on HEB at: www.wallstequities.com/registration/?symbol=HEB
iBio
New York-based iBio Inc.'s stock jumped 6.68%, finishing yesterday's session at $0.20 with a total trading volume of 1.17 million shares. The stock is trading above their 50-day moving average by 9.74%. Shares of the Company, which focuses on developing and commercializing pharmaceutical product applications using its platform in the US and internationally, have an RSI of 56.07. Aspiring Member, please take a moment to register below for your free research report on IBIO at: www.wallstequities.com/registration/?symbol=IBIO
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected] Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
Advertisement
WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on GRFS, HTBX, HEB, and IBIO which can be accessed for free by signing up to www.wallstequities.com/registration. Pre-market, WallStEquities.com covers the Biotechnology industry, which is a highly interdisciplinary field that combines biological sciences with engineering technologies to manipulate living organisms and biological systems to produce products that advances Healthcare, Medicine, Agriculture, Food, Pharmaceuticals, and Environment control. Stocks in today's lineup are: Grifols S.A. (NASDAQ: GRFS), Heat Biologics Inc. (NASDAQ: HTBX), Hemispherx Biopharma Inc. (NYSE AMER: HEB), and iBio Inc. (NYSE AMER: IBIO). All you have to do is sign up today for this free limited time offer by clicking the link below. www.wallstequities.com/registration
Advertisement
Grifols
Shares in Barcelona, Spain headquartered Grifols S.A. rose slightly by 0.18%, ending Wednesday's trading session at $22.83. The stock recorded a trading volume of 177,056 shares. The Company's shares have gained 31.43% over the past year. The stock is trading 4.69% above its 200-day moving average. Moreover, shares of Grifols, which develops, manufactures, and distributes a range of plasma derivative products primarily in the European Union, Spain, the US, Canada, and internationally, have a Relative Strength Index (RSI) of 35.78.
On February 06th, 2018, Grifols has received approval from the US FDA for a new higher potency formulation of its HyperRAB® rabies immune globulin [human] for rabies postexposure prophylaxis (treatment of a person immediately after exposure to the rabies virus). The new formulation is twice the potency (300 IU/mL) of currently available rabies immune globulin options. Get the full research report on GRFS for free by clicking below at: www.wallstequities.com/registration/?symbol=GRFS
Heat Biologics
Durham, North Carolina-based Heat Biologics Inc.'s stock declined 2.37%, closing the day at $2.88 with a total trading volume of 76,276 shares. The stock is trading 24.32% below their 50-day moving average. Shares of the Company, which focuses on the development and commercialization of novel allogeneic therapies for a range of cancers and infectious diseases in the US, have an RSI of 37.95.
On January 30th, 2018, Heat Biologics announced that it is hosting an analyst and investor event to present Phase-2 results from its HS-110 (viagenpumatucel-L) study in combination with the Bristol-Myers Squibb checkpoint inhibitor, nivolumab (Opdivo®), in patients with advanced non-small cell lung cancer, whose cancers have progressed after treatment with one or more lines of therapy. The presentation will take place on February 28th, 2018, at 8:00 a.m. in New York City. Access the free research report on HTBX now by signing up at: www.wallstequities.com/registration/?symbol=HTBX
Hemispherx Biopharma
On Wednesday, shares in Philadelphia, Pennsylvania headquartered Hemispherx Biopharma Inc. recorded a trading volume of 322,111 shares. The stock ended the day 1.77% higher at $0.46. The Company's shares have advanced 4.84% in the past month, 35.82% in the previous three months, and 3.43% over the past year. The stock is trading above its 50-day and 200-day moving averages by 10.17% and 6.07%, respectively. Furthermore, shares of Hemispherx Biopharma, which engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the US, have an RSI of 46.58.
On January 29th, 2018, Hemispherx Biopharma announced that Thomas K. Equels, M.S. J.D., CEO, will be presenting at the BIO CEO & Investor Conference on February 12th, 2018, at 9:15 a.m. ET (the time may be subject to changes depending on the conference organizers) at the New York Marriott Marquis in New York City. His presentation will focus on the large size of potential markets for ME/CFS; immuno-oncology; and immune system amplification for enhanced viral vaccines. Are you already registered with Wall St. Equities? Do so now for free, and get the report on HEB at: www.wallstequities.com/registration/?symbol=HEB
iBio
New York-based iBio Inc.'s stock jumped 6.68%, finishing yesterday's session at $0.20 with a total trading volume of 1.17 million shares. The stock is trading above their 50-day moving average by 9.74%. Shares of the Company, which focuses on developing and commercializing pharmaceutical product applications using its platform in the US and internationally, have an RSI of 56.07. Aspiring Member, please take a moment to register below for your free research report on IBIO at: www.wallstequities.com/registration/?symbol=IBIO
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected] Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/technical-perspectives-on-biotech-stocks----grifols-heat-biologics-hemispherx-biopharma-and-ibio-300595676.html
SOURCE Wall St. Equities
